Want to see GB:VAL full AI Analyst Report?
Top Page
ValiRx plc
(LSE:VAL)
Select Model
Select Model
Rating:46Neutral
Price Target:
0.14 p
▼(-11.25% Downside)
Action:Reiterated
Date:10/22/26
The score is primarily held down by weak financial performance: minimal and declining revenue, persistent operating/net losses, and ongoing negative operating/free cash flow that erodes equity and assets. Technicals provide partial support from strong near-term momentum (RSI ~72.9 and price above the 20-day average), but the broader trend remains weaker versus longer-term moving averages and MACD is slightly negative. Valuation is also limited by negative earnings (negative P/E) and no available dividend yield.
Positive Factors
Minimal leverage
Minimal debt reduces interest and refinancing exposure and preserves financial flexibility relative to a highly leveraged biotech. Although the company remains cash-burning, its capital structure does not currently add a significant fixed repayment burden or compound operating weakness.
Negative Factors
Declining, very small revenue
Revenue remains too small to support the current operating base and declined materially year over year. This indicates that commercial scale has not yet been established, leaving the company dependent on future asset progress rather than recurring operating revenue over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal leverage
Minimal debt reduces interest and refinancing exposure and preserves financial flexibility relative to a highly leveraged biotech. Although the company remains cash-burning, its capital structure does not currently add a significant fixed repayment burden or compound operating weakness.
Read all positive factors
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.78M
Dividend YieldN/A
Average Volume (3M)20.07M
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-34.36%
EPS Growth57.45%
CountryUK
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume52,310,936
30 Day Avg. Volume20,073,509
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to trea...
ValiRx plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.67K | 31.37K | 49.77K | 9.60K | 0.00 | 0.00 |
| Gross Profit | -112.46K | -6.25K | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -1.49M | -2.18M | -1.86M | -2.04M | -2.38M | -1.45M |
| Net Income | -2.14M | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | ||||||
| Total Assets | 2.77M | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 970.56K | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 0.00 | 1.40K | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 120.82K | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 3.13M | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.36M | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.36M | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -2.59K | -13.58K | -38.16K | -306.18K | 0.00 | 0.00 |
| Financing Cash Flow | 1.81M | 759.35K | 3.00M | 1.12M | 2.26M | 7.34K |
ValiRx plc Technical Analysis
Negative
0.16
Price Trends
0.14
Negative
0.15
Negative
0.22
Negative
Market Momentum
<0.01
Negative
51.42
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.14, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.42 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.
ValiRx plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £46.28M | -3.71 | -409.57% | ― | ― | 18.57% | |
47 Neutral | £22.71M | -4.46 | -284.01% | ― | ― | -105.65% | |
46 Neutral | £1.78M | -0.71 | -71.49% | ― | -34.36% | 57.45% | |
45 Neutral | £24.96M | -3.20 | -559.87% | 17.86% | ― | 5.62% | |
44 Neutral | £107.89M | -5.09 | 128.87% | ― | -100.00% | -30.39% | |
42 Neutral | £4.78M | -1.75 | -93.92% | ― | ― | 55.56% |
* Healthcare Sector Average
GB:VAL
ValiRx plc
0.14
-0.34
-71.58%
GB:TCF
Evgen Pharma
0.18
-0.04
-16.67%
GB:IMM
ImmuPharma
4.00
-7.90
-66.39%
GB:SAR
Sareum Holdings
16.25
2.75
20.37%
GB:SCLP
Scancell Holdings
89.00
-7.50
-7.77%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
671.00
-309.00
-31.53%
ValiRx plc Corporate Events
Business Operations and StrategyM&A Transactions
ValiRx sees value boost from Ambrose’s AM-Pharma acquisition
Positive
Oct 21, 2026
ValiRx plc has highlighted the impact of Ambrose Healthcare Ltd’s acquisition of AM-Pharma on its own position, after Ambrose disclosed a deal worth up to €161 million that triggered a share price move in ValiRx. Through its 54.14% own...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
ValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolio
Positive
Sep 15, 2026
ValiRx has tightened its operations in the first half of 2026, fully implementing a lean strategy that cut administrative costs and delivered additional annual savings, while refocusing Inaphaea BioLabs on supporting the company’s own pipeli...
Business Operations and StrategyRegulatory Filings and Compliance
ValiRx bolsters Cytolytix cancer IP with new European patent and delivery platform filing
Positive
Aug 10, 2026
ValiRx plc has strengthened the intellectual property position of its majority-owned subsidiary Cytolytix, with the European Patent Office indicating its intention to grant a second European patent covering polyleucine-based anti-cancer peptides l...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.